Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology
Vivos Therapeutics (NASDAQ:VVOS) said the U.S. Patent and Trademark Office issued U.S. Patent No. 12,697,190, a continuation of a 2024 patent, to broaden IP protection for its Vivos CARE oral device technology for obstructive sleep apnea. The company says the layered patents are harder for competitors to design around and support its FDA-cleared devices for severe adult and pediatric OSA.
How this was made
The 30-second read
Why it matters
The newly issued U.S. patent (a continuation layered on an earlier 2024 patent) is positioned as broader protection that is more difficult for competitors to design around, reinforcing Vivos’ IP portfolio for its flagship technology.
Market read
This is a company-specific IP milestone for VVOS, but it is not accompanied by new financial results, adoption metrics, or additional regulatory clearances.
What to watch
Investors may need to track whether the patent claims map to the most commercially adopted device features, and whether competitors have alternative technologies that bypass the protected aspects.
Background
Vivos CARE is an FDA-cleared oral medical device platform for obstructive sleep apnea, with clearances for severe OSA in adults and moderate-to-severe OSA in children ages 6 to 17.
Ticker impact
Vivos Therapeutics received a new U.S. patent (No. 12,697,190) expanding protection for its Vivos CARE oral device technology for OSA.
Near-term impact likely modest unless investors view the broader claims as materially reducing competitive risk; longer-term sentiment may improve for commercialization confidence.
The article is a first report of a newly issued patent and frames it as harder to design around, but it provides no new revenue, adoption, or FDA/regulatory milestone data.
Market effects
Supports the broader medical device theme that IP layering can be a competitive moat in sleep apnea oral appliance markets.
No clear regional spillover beyond U.S. patent issuance.
Limited, since the disclosure is specifically about a U.S. patent and does not mention international filings or enforcement.
Counterpoint
Broader patent language may still face validity or design-around challenges, so the market may over-discount the competitive protection benefit.
Key entities
- companyVivos Therapeutics
NASDAQ-listed medical device company whose Vivos CARE oral technology received a newly issued U.S. patent expanding IP protection.
- regulatorU.S. Patent and Trademark Office
Issued U.S. Patent No. 12,697,190 covering aspects of Vivos CARE technology.
- product_platformVivos CARE
Flagship oral medical device technology for obstructive sleep apnea referenced as covered by the new patent.
